NASDAQ:ZNTL Zentalis Pharmaceuticals Q1 2026 Earnings Report $4.03 -0.07 (-1.59%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Zentalis Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.49Beat/MissN/AOne Year Ago EPSN/AZentalis Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AZentalis Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Zentalis Pharmaceuticals Earnings HeadlinesZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerMay 5 at 8:00 AM | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 6 at 1:00 AM | Weiss Ratings (Ad)Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerApril 21, 2026 | globenewswire.comZentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the TargetApril 20, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at ...April 18, 2026 | finance.yahoo.comSee More Zentalis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email. Email Address About Zentalis PharmaceuticalsZentalis Pharmaceuticals (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies. The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers. In addition to ZN-c3, Zentalis’ pipeline includes programs targeting Polo-like kinase 1 (PLK1) and other novel oncogenic pathways. Preclinical studies conducted by the company have demonstrated promising activity across multiple tumor models, supporting further advancement of these candidates into human trials. Zentalis applies an integrated discovery and development model, combining computational chemistry, structural biology and in-house medicinal chemistry to accelerate the identification of potent and selective drug candidates. The company collaborates with leading contract research organizations and academic institutions to support its preclinical and clinical research programs, with the goal of streamlining the path from discovery through clinical proof-of-concept. Founded in 2017 and headquartered in New Haven, Connecticut, Zentalis Pharmaceuticals completed its initial public offering in 2020. The company is led by President and Chief Executive Officer Robert Farrell, Ph.D., whose experience in oncology drug discovery guides the organization’s strategic direction. Zentalis continues to advance its oncology pipeline with the aim of bringing novel treatment options to patients worldwide.View Zentalis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Years in the Making, AMD’s Upside Movement Has Just BegunPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026 Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
